ZYBERNO
Stock Report
Updated Aug 31, 2026

GH Research PLC (GHRS)

Healthcare • NASDAQ

$27.94

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
GH Research PLC (GHRS) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-136.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

GH Research PLC (GHRS) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:27.94
Market Cap:$1.73B

Valuation Multiples (2)

P/B Ratio:6.20x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.49B

Price Action & Momentum (3)

Momentum Percentile:93 / 100
% of 52-Week High:88.9%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:0.5%
Fundamental Growth Rate (g):-0.6%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:34.13x
Quick Ratio:34.13x
Cash Ratio:29.39x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-335.46x
Times Interest Earned:-335.46

Capital Structure (4)

Working Capital:277,596,000.00
Cash And Cash Equivalents:246,251,000.00
Long Term Debt:$0.00
Net Debt:-$246.25M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$60.72M

Bottom Line Performance (3)

-$48.26M
Income Before Tax:$0.00
Ebitda Ttm:-60,383,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:$0.00
Interest Expense:181,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$288.23M
Current Assets:$285.98M
Ppe Net:620,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:8,527,000.00
Current Liabilities:8,380,000.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$279.70M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,773,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$43.55M-$43.67M

Investment Activities (1)

Investing Cash Flow:$8.79M

Financing Activities (3)

Financing Cash Flow:-$71.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.78

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.70

Book Value & Capital (2)

Book Value Per Share:$4.51
Cash Per Share:3.97

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.5%
Fundamental Growth Rate (g):-0.6%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:GHRS
Company Name:GH Research PLC
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:Ireland

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:62.03M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 18:12:02 UTC
Data Timestamp:2026-08-31T18:12:02.374938
Scroll to Top